xarelto

J&J wants to expand marketing for drug

According to a story in the Washington Post, Johnson & Johnson has applied to the U.S. Food and Drug Administration to get approval of another use for its anti-clotting drug Xarelto.

Johnson & Johnson currently markets Xarelto for reducing the risk of blood clots in patients after knee or hip replacement surgery, and reducing the risk of stroke and other blood clots in people with a type of irregular heartbeat. The company ...

continue reading...

Bayer expects new drugs to generate billions

German corporation Bayer has announced that its four most promising drugs, led by newly-launched anti-clotting pill Xarelto, may account for combined annual sales of as much as $6.5 billion, according to a Reuters report.

The report says Bayer’s healthcare division is aiming for sales of roughly $26.2 billion in 2014, up from $22.4 billion last year.

The company said prescription drug sales were set to rise to about $15 billion by 2014, up 16 percent from 2011, fueled largely by new product ...

continue reading...
Page 5 of 5 12345